Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Fred Hutchinson Cancer Center · with National Cancer Institute (NCI) · NCT04515810
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 400
- US sites recruiting
- 1
- Study start
- February 18, 2025
- Record last updated
- August 17, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors. The development of the PACT mobile app may help future patients incorporate their social network (typically, but not exclusively, family) into the advance care planning process.
Being studied: Internet-Based Intervention; Best Practice; Telephone-Based Intervention; Questionnaire Administration; Post-intervention qualitative feedback interview
Conditions: Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Hematologic Malignancy; Refractory Hematologic Malignancy
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- PATIENT: Diagnosis of poor prognosis advanced cancer defined as locally advanced or metastatic solid cancer and/or disease progression following at least first line systemic therapy and/or relapsed or refractory hematologic cancer.
- PATIENT: Have internet access through a computer or a mobile device; the principal investigator (PI) will ensure that those who have access to a computer or mobile device have access to a computer or mobile device with internet access to ensure they can complete study procedures.
- PATIENT: The ability to provide informed consent.
- PATIENT: Identification of a loved support person if one is available; patients who are unable to identify a support person willing to participate with them will be allowed to continue in the study on their own.
- PATIENT: 18 years of age or older.
- SUPPORT PERSON: The person (family member or friend) whom the patient indicates being a support person.
- SUPPORT PERSON: English speaking.
- SUPPORT PERSON: 18 years of age or older and able to provide informed consent.
- PROVIDER: Current clinical practice and/or research with advanced cancer patients.
- PROVIDER: A history of 3+ years working with advanced cancer patients.
- PROVIDER: 18 years of age or older. Providers across disciplines (e.g., social work, oncology) will be enrolled.
Exclusion Criteria
- PATIENT: Not fluent in English.
- PATIENT: Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of >= 6) to be delivered by trained study research staff during screening.
- PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer).
- PATIENT: Currently receiving hospice at the time of enrollment.
- PATIENT: Children and young adults under age 18.
Recruiting US locations
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA 98109
Site contact: Claudia De Los Santos, B.S. · 206-667-1565 · cdelossa@fredhutch.org
Study contacts (from the official record)
- Claudia De Los Santos, B.S. · 206-667-1565 · cdelossa@fredhutch.org
- Megan Shen, PhD · 206-667-4172 · mshen2@fredhutch.org
Similar studies in Washington
All healthy volunteers studies in Washington →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Seattle, WA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
GlaxoSmithKline
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Seattle, WA + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Seattle, WA + 9 other US sites
- Eligibility basics
- Ages 12–60